Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411986 | 0.91 | KMT2A (0.43) | KMT2AMEN1RAB9ANAMPTCNR1 | |
| SCHEMBL411983 | 0.88 | KMT2A (0.42) | KMT2AMEN1RAB9ANAMPTCNR1 | |
| SCHEMBL12290584 | 0.84 | ALDH1A1 (0.40) | KDM4EKMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL28948777 | 0.81 | NPC1 (0.52) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL29742188 | 0.81 | NPC1 (0.52) | KMT2AMEN1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL3726907 | 0.81 | CXCR2 (0.41) | KMT2AALDH1A1RAB9ACXCR2NPC1 | |
| SCHEMBL5918956 | 0.81 | HDAC1 (0.41) | KDM4EKMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL2380393 | 0.80 | CA1 (0.49) | KDM4EALDH1A1L3MBTL1RAB9AGAA | |
| SCHEMBL17378778 | 0.80 | MEN1 (0.43) | KMT2AMEN1RAB9ACXCR2NPC1 | |
| SCHEMBL420518 | 0.79 | SAE1 (0.49) | KMT2AMEN1ALDH1A1RAB9ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249129-B2 | Morpholino substituted urea derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249129-B2 | Morpholino substituted urea derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249129-B2 | Morpholino substituted urea derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| EP-2542536-B1 | Morpholino substituted urea derivatives as mtor inhibitors | CELLZOME LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| EP-2542536-B1 | Morpholino substituted urea derivatives as mtor inhibitors | CELLZOME LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| EP-2406258-B1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LTD (GB) | 2014-12-03 | — | — | EP | disclosed |
| EP-2406258-B1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LTD (GB) | 2014-12-03 | — | — | EP | disclosed |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED | 2014-10-02 | — | — | US | disclosed |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED | 2014-10-02 | — | — | US | disclosed |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED | 2014-10-02 | — | — | US | disclosed |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2542536-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | Cellzome Limited (GB) | 2013-01-09 | — | — | EP | disclosed |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2406258-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Cellzome Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011107585-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2011-09-09 | — | — | WO | disclosed |
| WO-2010103094-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103094-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065202-A1 | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | KDM4E 1225/4885KMT2A 2786/4885MEN1 1273/4885 |
| US-20140296234-A1 | PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | KDM4E 1225/4885KMT2A 2786/4885MEN1 1273/4885 |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | MTOR, EIF4E, EIF4A1 | KDM4E 300/4885KMT2A 1849/4885MEN1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.